Aurélie Beaufrère
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aurélie Beaufrère has a total of 215 co-authors. Here are the top co-authors by number of shared publications:
Valérie Paradis
Department of Pathology, APHP-Beaujon Hospital, Université Paris Cité, Paris, France
14 shared publicationsMiguel Albuquerque
Department of Pathology, Beaujon Hospital, FHU MOSAIC, SiRIC InsiTu, AP-HP. Nord-Université Paris Cité, Clichy, France
7 shared publicationsFrançois Cauchy
Centre de Recherche sur l'Inflammation, INSERM UMR 1149 Paris France
5 shared publicationsMickael Lesurtel
AP-HP.Nord, Department of HPB Surgery & Liver Transplantation, Beaujon Hospital, Université Paris Cité, Clichy, France
5 shared publicationsMohamed Bouattour
Department of Liver Cancer and Innovative Therapy Unit, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, AP-HP. Nord, Clichy, France Université Paris Cité, Centre de Recherche Sur L'Inflammation (CRI), INSERM, U1149, CNRS, Paris, France
5 shared publicationsGwladys Lubuela
Université Paris Cité, Centre de Recherche sur L'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France
4 shared publications
Latest Publications
- 15 November 2026
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- p. 102969
Biliary Adenofibroma: an Enigmatic Liver Tumor with Inconsistent Outcomes
- 15 November 2026
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- p. 102969
Biliary Adenofibroma: an Enigmatic Liver Tumor with Inconsistent Outcomes
- Open Access
- 20 May 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (8) , 101900
Combining MRI criterion and pathology-based microvascular invasion improves prognostic stratification in early HCC
- 20 May 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (8) , 101900
Open AccessCombining MRI criterion and pathology-based microvascular invasion improves prognostic stratification in early HCC
- Open Access
- 1 May 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (7) , 101874
Vessels encapsulating tumor clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab–bevacizumab
- 1 May 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (7) , 101874
Open AccessVessels encapsulating tumor clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab–bevacizumab
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Signatures moléculaires pronostiques et théranostiques dans les tumeurs primitives hépatiques malignes : développement de nouvelles approches méthodologiques
Les tumeurs primitives hépatiques malignes sont des tumeurs de mauvais pronostic, diagnostiquées tardivement et peu sensibles aux traitements systémiques. Le carcinome hépatocellulaire (CHC) et le cholangiocarcinome sont les deux principales tumeurs malignes primitives hépatiques. Si des facteurs histopronostiques et théranostiques sont reconnus pour ces tumeurs, ils sont le plus souvent non accessibles en pré-opératoire. L'objectif de ce travail était d'identifier des signatures moléculaires par des approches méthodologiques innovantes, pronostiques applicables sur prélèvement biopsique [NanoString et ddPCR pour l'identification des mutations du promoteur de TERT (pTERT)], et théranostiques (modèle de culture d'organoïdes tumoraux) dans les tumeurs primitives hépatiques malignes notamment dans le carcinome hépatocellulaire. Premièrement, nous avons démontré la faisabilité de la recherche des mutations pTERT par ddPCR sur des échantillons biopsiques de nodules hépatocellulaires <2cm obtenus en routine. Nos résultats soulignent également que certains nodules dysplasiques (mutés pTERT) devraient être considérés comme des CHC, malgré leur classification histologique et traités comme tels, et que certains critères morphologiques sont indépendamment associés aux mutations pTERT. Deuxièmement, nous avons identifié une signature transcriptomique de 6 gènes (ROS1, UGT2B7, FAS, ANGPTL7, GMNN, MKI67) associée à l'invasion vasculaire microscopique dans le CHC, facteur pronostique majeur, applicable sur biopsies fixées en formol et incluses en paraffine grâce à la technologie Nanostring. Troisièmement, nous avons montré une modification du profil immunitaire des CHC préalablement traités par chimio-embolisation transartérielle, suggérant un potentiel impact bénéfique de ce traitement utilisé en combinaison avec l'immunothérapie afin d'optimiser la réponse tumorale. Enfin, nous avons développé un protocole standardisé de culture d'organoïdes et d'isolation de cellules endothéliales à partir de tumeurs primitives hépatiques malignes humaines dans la perspective d'identifier des facteurs théranostiques dans ces tumeurs. Au total, l'ensemble des résultats ont permis de mettre en évidence des signatures moléculaires pronostiques et de développer des outils qui pourraient être utilisés dans le futur comme une aide à la stratification thérapeutique chez les patients atteints de tumeurs malignes primitives hépatiques.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Signatures moléculaires pronostiques et théranostiques dans les tumeurs primitives hépatiques malignes : développement de nouvelles approches méthodologiques
Les tumeurs primitives hépatiques malignes sont des tumeurs de mauvais pronostic, diagnostiquées tardivement et peu sensibles aux traitements systémiques. Le carcinome hépatocellulaire (CHC) et le cholangiocarcinome sont les deux principales tumeurs malignes primitives hépatiques. Si des facteurs histopronostiques et théranostiques sont reconnus pour ces tumeurs, ils sont le plus souvent non accessibles en pré-opératoire. L'objectif de ce travail était d'identifier des signatures moléculaires par des approches méthodologiques innovantes, pronostiques applicables sur prélèvement biopsique [NanoString et ddPCR pour l'identification des mutations du promoteur de TERT (pTERT)], et théranostiques (modèle de culture d'organoïdes tumoraux) dans les tumeurs primitives hépatiques malignes notamment dans le carcinome hépatocellulaire. Premièrement, nous avons démontré la faisabilité de la recherche des mutations pTERT par ddPCR sur des échantillons biopsiques de nodules hépatocellulaires <2cm obtenus en routine. Nos résultats soulignent également que certains nodules dysplasiques (mutés pTERT) devraient être considérés comme des CHC, malgré leur classification histologique et traités comme tels, et que certains critères morphologiques sont indépendamment associés aux mutations pTERT. Deuxièmement, nous avons identifié une signature transcriptomique de 6 gènes (ROS1, UGT2B7, FAS, ANGPTL7, GMNN, MKI67) associée à l'invasion vasculaire microscopique dans le CHC, facteur pronostique majeur, applicable sur biopsies fixées en formol et incluses en paraffine grâce à la technologie Nanostring. Troisièmement, nous avons montré une modification du profil immunitaire des CHC préalablement traités par chimio-embolisation transartérielle, suggérant un potentiel impact bénéfique de ce traitement utilisé en combinaison avec l'immunothérapie afin d'optimiser la réponse tumorale. Enfin, nous avons développé un protocole standardisé de culture d'organoïdes et d'isolation de cellules endothéliales à partir de tumeurs primitives hépatiques malignes humaines dans la perspective d'identifier des facteurs théranostiques dans ces tumeurs. Au total, l'ensemble des résultats ont permis de mettre en évidence des signatures moléculaires pronostiques et de développer des outils qui pourraient être utilisés dans le futur comme une aide à la stratification thérapeutique chez les patients atteints de tumeurs malignes primitives hépatiques.
- Open Access
- 26 February 2026
- Published by Elsevier in Annales de Pathologie
- Vol. 46 (6) , 566-568
Lésions hépatiques mésenchymateuses chez un patient immunodéprimé
- 26 February 2026
- Published by Elsevier in Annales de Pathologie
- Vol. 46 (6) , 566-568
Open AccessLésions hépatiques mésenchymateuses chez un patient immunodéprimé
- 6 February 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 84 (6) , 1121-1130
Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma
- 6 February 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 84 (6) , 1121-1130
Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma
- Open Access
- 27 January 2026
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 75 (2) , 51
Tumor-associated macrophages in head and neck carcinoma: clinicopathological correlations and implications for immunotherapy
Tumor-associated macrophages (TAMs) and other PD-L1-expressing immune cells play a key role in head and neck squamous cell carcinoma (HNSCC). As PD-1 inhibitors have become standard therapy for recurrent/metastatic disease and are now used perioperatively in locally advanced resectable cases, understanding their impact on TAMs dynamics is critical. This study investigated the association between clinical features and TAMs prevalence in HNSCC, and their potential role in tumor progression and resistance to PD-1 blockade. Tumor samples from HNSCC patients were analyzed by simplex and multiplex immunohistochemistry, and fresh tumor slices were cultured ex vivo with PD-1 inhibitors. CD68 + and CD163 + macrophages and PD-L1 expression were quantified and correlated with clinical parameters. In a tissue microarray cohort of 96 patients, CD68 + and CD163 + macrophages were more abundant in oral and oropharyngeal tumors compared to laryngeal and hypopharyngeal carcinomas ( p = 0.001 and p = 0.06, respectively). In 10% of cases, TAMs formed a barrier between tumor nests and immune infiltrates. Among nine patients with matched pre- and post-immunotherapy samples, TAMs density significantly increased post-treatment ( p = 0.01 and p = 0.03), with CD163 + macrophages clustering at the tumor periphery in 78% of cases. Multiplex staining confirmed this spatial reorganization. Ex vivo exposure to PD-1 inhibitors reproduced the increase in TAMs. These results suggest that PD-1 blockade may foster M2-like macrophage accumulation, potentially contributing to immune evasion. This underscores the need for prospective studies and the development of macrophage-targeted strategies, particularly in the emerging context of perioperative immunotherapy in HNSCC.
- 27 January 2026
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 75 (2) , 51
Open AccessTumor-associated macrophages in head and neck carcinoma: clinicopathological correlations and implications for immunotherapy
Tumor-associated macrophages (TAMs) and other PD-L1-expressing immune cells play a key role in head and neck squamous cell carcinoma (HNSCC). As PD-1 inhibitors have become standard therapy for recurrent/metastatic disease and are now used perioperatively in locally advanced resectable cases, understanding their impact on TAMs dynamics is critical. This study investigated the association between clinical features and TAMs prevalence in HNSCC, and their potential role in tumor progression and resistance to PD-1 blockade. Tumor samples from HNSCC patients were analyzed by simplex and multiplex immunohistochemistry, and fresh tumor slices were cultured ex vivo with PD-1 inhibitors. CD68 + and CD163 + macrophages and PD-L1 expression were quantified and correlated with clinical parameters. In a tissue microarray cohort of 96 patients, CD68 + and CD163 + macrophages were more abundant in oral and oropharyngeal tumors compared to laryngeal and hypopharyngeal carcinomas ( p = 0.001 and p = 0.06, respectively). In 10% of cases, TAMs formed a barrier between tumor nests and immune infiltrates. Among nine patients with matched pre- and post-immunotherapy samples, TAMs density significantly increased post-treatment ( p = 0.01 and p = 0.03), with CD163 + macrophages clustering at the tumor periphery in 78% of cases. Multiplex staining confirmed this spatial reorganization. Ex vivo exposure to PD-1 inhibitors reproduced the increase in TAMs. These results suggest that PD-1 blockade may foster M2-like macrophage accumulation, potentially contributing to immune evasion. This underscores the need for prospective studies and the development of macrophage-targeted strategies, particularly in the emerging context of perioperative immunotherapy in HNSCC.
- Open Access
- 10 January 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (6) , 1491-1494
Occult rat hepatitis E virus infection as a cause of cirrhosis and posttransplant recurrence: Insights into the role of metagenomics
- 10 January 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (6) , 1491-1494
Open AccessOccult rat hepatitis E virus infection as a cause of cirrhosis and posttransplant recurrence: Insights into the role of metagenomics
- Open Access
- 13 November 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (2) , 101675
Self-supervised learning to predict intrahepatic cholangiocarcinoma transcriptomic classes on routine histology
- 13 November 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (2) , 101675
Open AccessSelf-supervised learning to predict intrahepatic cholangiocarcinoma transcriptomic classes on routine histology
- Open Access
- 28 August 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (8) , e0323270
Exploring the risks of over-reliance on AI in diagnostic pathology. What lessons can be learned to support the training of young pathologists?
The integration of Artificial Intelligence (AI) algorithms into pathology practice presents both opportunities and challenges. Although it can improve accuracy and inter-rater reliability, it is not infallible and can produce erroneous diagnoses, hence the need for pathologists to always check predictions. This critical judgment is particularly important when algorithm errors could lead to high-impact negative clinical outcomes, such as missing an invasive carcinoma. However, the influence of AI tools on pathologists’ decision-making is not well explored. This study aims to evaluate the impact of a previously developed AI tool on the diagnostic accuracy and inter-rater reliability among pathologists, while assessing whether pathologists maintain independent judgment of AI predictions. Eight pathologists from different hospitals and with varying levels of experience, participated in the study. Each of them reviewed 115 slides of laryngeal biopsies, including benign epithelium, low-grade and high-grade dysplasia, and invasive squamous carcinomas. The study compared diagnostic outcomes with and without AI assistance. The reference labels were established by an expert’s double-blind review. Results show that assisted pathologists had a higher accuracy for high-grade dysplasia, invasive carcinoma and improved inter-rater reliability. However, cases of over-reliance on AI have been observed, resulting in the omission of correctly diagnosed invasive carcinomas during the unassisted examination. The false predictions on these carcinoma slides were labeled with a low confidence score, which was not considered by the less experienced pathologists, showing the risk that they would follow the AI prediction without enough critical judgment or expertise. Our study emphasizes the potential over-reliance of pathologists on AI models and the potential harmful consequences, even with the advancement of powerful algorithms. The integration of confidence scores and the education of pathologists to use this tool could help to optimize the safe integration of AI into pathology practice.
- 28 August 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (8) , e0323270
Open AccessExploring the risks of over-reliance on AI in diagnostic pathology. What lessons can be learned to support the training of young pathologists?
The integration of Artificial Intelligence (AI) algorithms into pathology practice presents both opportunities and challenges. Although it can improve accuracy and inter-rater reliability, it is not infallible and can produce erroneous diagnoses, hence the need for pathologists to always check predictions. This critical judgment is particularly important when algorithm errors could lead to high-impact negative clinical outcomes, such as missing an invasive carcinoma. However, the influence of AI tools on pathologists’ decision-making is not well explored. This study aims to evaluate the impact of a previously developed AI tool on the diagnostic accuracy and inter-rater reliability among pathologists, while assessing whether pathologists maintain independent judgment of AI predictions. Eight pathologists from different hospitals and with varying levels of experience, participated in the study. Each of them reviewed 115 slides of laryngeal biopsies, including benign epithelium, low-grade and high-grade dysplasia, and invasive squamous carcinomas. The study compared diagnostic outcomes with and without AI assistance. The reference labels were established by an expert’s double-blind review. Results show that assisted pathologists had a higher accuracy for high-grade dysplasia, invasive carcinoma and improved inter-rater reliability. However, cases of over-reliance on AI have been observed, resulting in the omission of correctly diagnosed invasive carcinomas during the unassisted examination. The false predictions on these carcinoma slides were labeled with a low confidence score, which was not considered by the less experienced pathologists, showing the risk that they would follow the AI prediction without enough critical judgment or expertise. Our study emphasizes the potential over-reliance of pathologists on AI models and the potential harmful consequences, even with the advancement of powerful algorithms. The integration of confidence scores and the education of pathologists to use this tool could help to optimize the safe integration of AI into pathology practice.